

DAY 1: SUNDAY, 25 NOVEMBER 2012

0900 – 1600	REGISTRATION	
1430 – 1605	SCIENTIFIC SESSION 1: PRE-CONFERENCE SYMPOSIUM ON NUCLEAR CARDIOLOGY	Auditorium, Ground Floor
	Session Chairpersons: 1. Dr Pankaj Dougall, Nuclear Medicine and PET-CT, Max Super Speciality Hospitals, New Delhi, India 2. Dr Kok Tian Yue, Nuclear Medicine and PET, Singapore General Hospital, Singapore	
1430 – 1455 PC-1	Myocardial Viability – Implications for Clinicians Dr Carlos D Libhaber, Nuclear Medicine, University of the Witwatersrand, Chris Hanani Baragwanath Hospital, Johannesburg, South Africa	
1455 – 1520 PC-2	Role of Radionuclide Imaging in Heart Failure Prof Zuo-Xiang He, Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, Beijing, China	
1520 – 1540 PC-3	New Experimental Tracers for Myocardial Ischemia Prof Henry Bom, Nuclear Medicine, Chonnam National University Hospital, Jeonnam, Korea	
1540 – 1605 PC-4	Assessment of Cardiac Dysynchrony: A Nuclear Approach Prof Chetan Patel, Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India	
1605 – 1630	COFFEE / TEA / TRADE EXHIBITION	
1630 – 1830	SCIENTIFIC SESSION 2: PRE-CONFERENCE SYMPOSIUM ON ARCTIC ENVIRONMENT	Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Mauri Yla-Kotola, University of Lapland, Finland 2. Prof Kalevi Kairemo, Molecular Radiotherapy & Nuclear Medicine, International Comprehensive Cancer Center Docrates, Helsinki, Finland	
1630 – 1655 PC-5	Hospitals, Hospitality and Hosting Health – An Arctic Avenue Prof Johan Edelheim, Multidimensional Tourism Institute, University of Lapland, Rovaniemi, Finland	
1655 – 1705 PC-6	Human Thermal Responses During Reindeer Safaris in Cold Dr Susanna Paakkola, Arctic Centre, University of Lapland, Rovaniemi, Finland	
1705 – 1730 PC-7	Northern Lights Through the Eyes of a Space Scientist Prof Thomas Ulich, Director, Sodankyla Geophysical Observatory, University of Oulu, Oulu, Finland	
1730 – 1745 PC-8	Glaciological Research in Svalbard Dr Martina Schafer, Arctic Centre, University of Lapland, Rovaniemi, Finland	
1745 – 1805 PC-9	Arctic Sculptures, Snow & Ice Prof Timo Jokela, University of Lapland, Rovaniemi, Finland	
1805 – 1830 PC-10	Many Faces of Love Prof Kaarina Maatta, University of Lapland, Rovaniemi, Finland	
1930 – 2200	WELCOME DINNER	Restaurant Okta, Ground Floor Hotel Levi Panorama
2200	END OF DAY 1	

DAY 2: MONDAY, 26 NOVEMBER 2012

0800 – 1600	REGISTRATION	
0830 – 0900	SCIENTIFIC SESSION 3: OPENING	Auditorium, Ground Floor
	Welcome Prof Kalevi Kairemo, Local Organising Chairman, ICRT 2012	
	Opening Remarks Prof Ajit Kumar Padhy, International Organising Chairman, ICRT 2012 & President-WARMTH	
	WARMTH Candle Lighting Ceremony Prof Harvey Turner, Prof Ajit Kumar Padhy, Prof Richard P Baum, Prof Alan Perkins, Prof Kalevi Kairemo & Other Members of WARMTH Governing Body	
0900 – 1100	SCIENTIFIC SESSION 4: THYROID DISEASES I	Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Mike Sathekge, Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa 2. Prof Ralph McCready, Nuclear Medicine, Royal Sussex County Hospital, Brighton, United Kingdom	
0900 – 0920 S-1	Subclinical Hyperthyroidism – To Treat or Not to Treat with Radioiodine A/Prof Grzegorz Kaminski, Endocrinology & Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland	
0920 – 0940 S-2	Graves' Ophthalmopathy & Radioiodine Therapy Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines	
0940 – 1000 S-3	Thyroid Cancer and Nuclear Accident Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan	
1000 – 1020 S-4	Use of Rh-TSH (Thyrogen) in Thyroid Cancer – A Review Dr Sze Ting Lee, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia	
1020 – 1040 S-5	Modern Imaging in Detection of Iodine Negative-Tg Positive Differentiated Thyroid Cancer Prof Jasna Mihailovic, Nuclear Medicine, Oncology Institute of Vojvodina, Novi Sad, Serbia	
	ORAL PRESENTATIONS	Auditorium, Ground Floor
1040 – 1050 O-1	Efficacy of Different Protocols of Radioiodine Therapy for Treatment of Toxic Nodular Goiter: Systematic Review and Meta-Analysis of the Literature Dr R Zakavi, et al (Iran)	
1050 – 1100 O-2	Early Radioiodine Ablation Post Thyroidectomy with Recombinant TSH (r-TSH) Stimulation and its Impact on Performance Status, Versus Thyroxine Abstinence Protocol in Differentiated Thyroid Carcinoma : Initial Results of a Randomized Prospective Clinical Trial Dr P Choudhary, et al (India)	
1100 – 1130	COFFEE / TEA / TRADE EXHIBITION	
1100 – 1130	POSTER PRESENTATIONS	
	Session Coordinators: 1. Dr Ruben Ogbac, Nuclear Medicine, St Luke's Medical Center, Quezon City, Philippines 2. Dr Erdenechimeg Sereegotov, Nuclear Medicine, First Central Hospital, Ulaanbaatar, Mongolia	
P-1	What is the Alternative to Radioiodine Therapy in Diffuse Pulmonary Metastasis from Papillary Thyroid Carcinoma in Children Dr Kaouthar Chatti, et al (Tunisia)	
P-2	Thyroid Cancer Treated at the Clinical Center Banja Luka. A Review of 5 Years Experience Dr Zvezdana Rajkovic, et al (Serbia)	
P-3	Optimization of 90Y-antiCD20 Preparation for Radioimmunotherapy Dr Amir R Jallilian, et al (Iran)	
P-4	Optimized Preparation of [64Cu]-DOTA-Trastuzumab for PET Applications Dr Amir R Jallilian, et al (Iran)	
P-5	Significance of Post-Therapy SPECT-CT Scan in Differentiated Thyroid Cancer Dr Rajesh Kumar, et al (India)	
P-6	Patient's Specific Dosimetry for Radioiodine Therapy of Thyroid Cancer and Comparison with Fixed Doses Dr Noreen Marwat, et al (Pakistan)	

DAY 2: MONDAY, 26 NOVEMBER 2012

P-7	Bone Metastases from Differentiated Thyroid Carcinoma: Clinical Features and Long Term Follow Up Dr Nurun Nahar, et al (Bangladesh)
P-8	Salivary Gland Tumor After Radioiodine Therapy for Well Differentiated Thyroid Carcinoma: A Case Report Prof Lutfun Nisa, et al (Bangladesh)
P-9	Radioactive Iodine Ablation in Children and Adolescents with Differentiated Thyroid Carcinoma Dr Yustia Tuti Jelani, et al (Indonesia)
P-10	The Advantages of Routine Radiothyroablation in Well Differentiated Thyroid Carcinoma Patients Dr Hapsari Indrawati, et al (Indonesia)
P-11	Clinical Outcome of Differentiated Thyroid Carcinoma with Lymph Node Metastasis : A Retrospective Analysis of Patients Treated at a Single Institute Dr Faria Nasreen, et al (Bangladesh)
P-12	Papillary Thyroid Carcinoma after Maximum Radioiodine Therapy with Persistent Disease (A Case Study) Dr Ryna Z Martiana, et al (Indonesia)
P-13	Clinical Behavior of Follicular Variant of Papillary Thyroid Carcinoma at INMU Dr Sadia Sultana, et al (Bangladesh)
P-14	Detection and Treatment of Lung Metastases in Differentiated Thyroid Carcinoma Dr Zeenat Jabin, et al (Bangladesh)
P-15	Clinical Significance of Thyroglobulin Antibody Pattern in Patients with Differentiated Thyroid Carcinoma: Preliminary Study Dr Ivana Dewi Mulyanto, et al (Indonesia)
P-16	Two Cases with Unusual Uptake in the Whole Body Scan with Radioiodine 131: Textiloma; Miliary Tuberculosis Dr Ben Rais Aouad Nozha, et al (Morocco)
P-17	A Rare Pediatric Case of Metastatic Papillary Thyroid Carcinoma in the Brain Dr Karina Michaela Dela Cruz, et al (Philippines)
P-18	Diagnostic Difficulty Due to Incidental Fibrous Dysplasia in a Patient with Metastatic Follicular Thyroid Cancer and the Possible Association of these Entities with McCune Albright Syndrome Dr Sumbul Zaheer, et al (Singapore)
P-19	The Value of PET/CT in the Diagnosis and Therapy of Thyroid Cancer Dr Emerita Barrenechea, et al (Philippines)
P-20	Radioiodine Treatment for Thyrotoxicosis in Childhood and Adolescence: Treatment and Outcome Dr Sirianong Namwongprom, et al (Thailand)
P-21	Follow-up of High Risk Thyroid Cancer Patients with Bone and Lung Metastases Dr Rosanna Morales, et al (Peru)
P-22	Low Dose Radioiodine Ablation for Differentiated Thyroid Carcinoma (DTC) - A Retrospective Analysis Dr Damayanthi KK Nanayakkara, et al (Sri Lanka)
P-23	Clinical Outcome of Radioactive Iodine Therapy Among Patients with Hyperthyroidism in St. Luke's Medical Center-Philippines Dr Irene Bandong, et al (Philippines)
P-24	Hürthle Cell Carcinoma – The Nuclear Medicine Specialist Point of View Dr Ana Ugrinska, et al (Macedonia)
P-25	Role of Thyroglobulin (Tg) Level and Whole-Body Scan (WBS) After I-131 Therapy in Patients with Differentiated Thyroid Cancer Dr Shankar Biswas, et al (Bangladesh)
P-26	Potential Response of Grave's Disease Associated with Thymic Hyperplasia After Radioactive Iodine 131 Therapy: A Case Report Dr Bonan A. Mendoza, et al (Philippines)
P-85	Experience with 30 mCi Iodine-131 Ablation Therapy for DTC in Sarawak General Hospital Dr Dahlia Saidin, et al (Malaysia)

DAY 2: MONDAY, 26 NOVEMBER 2012

1130 – 1305	SCIENTIFIC SESSION 5: BONES & JOINTS / METASTATIC BONE PAIN PALLIATION	Auditorium, Ground Floor
Session Chairpersons:		
1. Prof Izak Garty, Nuclear Medicine, Central Emek Hospital, Afula, Israel		
2. Dr Sze Ting Lee, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia		
1130 – 1150 S-10	Intermittent Pneumatic Compression: Effect on MDP Uptake – A Potential Method to Facilitate Therapy Prof Abdelhamid Elgazzar, Medical Faculty, University of Kuwait, Safat, Kuwait	
1150 – 1210 S-11	Radionuclide Imaging of Bone Metastases: Science & Practice Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom	
1210 – 1225 S-60	Radiosynovectomy-Procedure Review and Description of A Multicentre Study to Measure the Safety and Efficacy of Radiosynovectomy Performed with Y-90 Citrate Colloid and Re-186 Sulfide Dr James Warrington, Nuclear Medicine, London Health Sciences Centre, London, Canada	
1225 – 1245 S-12	Radiosynovectomy in the Treatment of Arthritis Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany	
1245 – 1305 S-19	Assessing Tuberculosis Response to Therapy Prof Mike Satheke, Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa	
1305 – 1400	LUNCH / TRADE EXHIBITION	Restaurant Okta, Ground Floor Hotel Levi Panorama
1400 – 1600	WARMTH GOVERNING BODY MEETING (GOVERNING BODY MEMBERS ONLY)	
1400 – 1613	SCIENTIFIC SESSION 6: THYROID DISEASES II	Auditorium, Ground Floor
Session Chairpersons:		
1. Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany		
2. Dr Achmad Hussein Sundawa Kartamihardja, Nuclear Medicine, Dr Hasan Sadikin General Hospital, Bandung, Indonesia		
1400 – 1425 S-7	Clinical Role of F-18 FDG PET/CT for Differentiated Thyroid Cancer Before and After High Dose I-131 Therapy Prof Henry Bom, Nuclear Medicine, Chonnam National University Hospital, Jeonnam, Korea	
1425 – 1445 S-8	Role of SPECT-CT in Diagnosis, Staging and Follow Up of Patients with Thyroid Diseases Dr Sonya Sergieva, Nuclear Medicine, Sofia Cancer Center, Sofia, Bulgaria	
1445 – 1500 S-9	Management of Differentiated Thyroid Cancer: A Single Centre Experience & Lessons Learnt in the Last 20 Years Dr Shazia Fatima, Nuclear Medicine, Nuclear Medicine, Oncology & Radiotherapy Institute, Islamabad, Pakistan	
1500 – 1525 S-6	Therapeutic Approaches in Thyroid Cancer – What is Next to Standard Treatment? Dr Daniel Putzer, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria	
ORAL PRESENTATIONS		
1525 – 1533 O-3	Clinical Significance of Measurement of Serum Anti Thyroglobulin Antibodies (ATgAb) in the Follow Up of Differentiated Thyroid Carcinoma Dr Javaid Irfan, et al (Pakistan)	
1533 – 1541 O-4	Consequences of Misadministration in Handling of Radiopharmaceuticals Prof Ajai Kumar Shukla (India)	
1541 – 1549 O-5	Experience with 177Lu-EDTMP Regarding Improvement in Quality of life and Bone Pain Palliation Dr Ghazal Jameel, et al (Pakistan)	
1549 – 1557 O-6	Hydroxyapatite Particles Labelled with Beta-Emitting Lanthanoids for Radiosynovectomy Dr Mohammad Sohaib, et al (Pakistan)	
1557 – 1605 O-7	The Pilot Study To Evaluate the Effectiveness of Radiosynoviorthesis (RSO) of Sacro-iliac Joints with Re-186 Dr Marika Vereb, et al (Germany)	
1605 – 1613 O-8	Radiation synovectomy with Yttrium (90Y) Citrate in rheumatoid arthritis patients- 5 years of follow up Dr Ljiljana Jaukovic, et al (Serbia)	

DAY 2: MONDAY, 26 NOVEMBER 2012

1613 – 1630	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION
1613 – 1630	POSTER PRESENTATIONS
	Session Coordinators: 1. Dr Ana Ugrinska, Institute of Pathophysiology and Nuclear Medicine, Skopje, Macedonia 2. Dr Anne Poksi, Nuclear Medicine Centre, East-Tallinn Central Hospital, Tallinn, Estonia
P-27	Effectiveness of Radiation Synovectomy with Yttrium (90Y) Citrate Related to Preexisting Radiological Damage in Rheumatoid Arthritis Patients Dr Boris Ajdinovic, et al (Serbia)
P-28	Treatment Efficacy of Sm-153 Lexidronate for Pain Management of Bone Metastases: The First Experience in Iran Dr Narjess-Khatoon Ayati, et al (Iran)
P-29	Clinical Characteristics, Efficacy of I-131 Therapy and Outcome of Patients with Differentiated Thyroid Cancer having Bone Metastases – A Retrospective Study Dr Sadaf Butt, et al (Pakistan)
P-30	Production, Quality Control and Biological Evaluation of 153Sm-isoPDTMP and 153Sm-TTHMP as a Possible Bone Palliation Agent Dr Zohreh Naseri, et al (Iran)
P-31	Effectiveness of Strontium -89 Therapy in Multiple Bony Metastases Patient with CA. Breast and CA.Prostate Dr Om Prakash Sinha, et al (India)
P-32	A Study on Srontium-90 Irradiation for Treatment of Post-Operative Conjunctival Squamous Cell Carcinoma Prof Raihan Hussain, et al (Bangladesh)
P-33	The Synthesis, Radiolabeling and First Biological Evaluation of a New 166Ho-Complex for Radiotherapy of Bone Metastases Dr Samaneh Zolghadri, et al (Iran)
P-34	Post- Therapy Precautions and Imaging Properties of Samarium 53 vs Strontium-89 Mr Rey Martin Jr Goco, et al (Philippines)
P-35	Semi-Quantitative Estimation of Samarium-153 Oxabifore Therapy Results of Metastatic Bone Disease in Mono - Regime and in Combination with Bisphosphonates Dr Nigora Rasulova, et al (Uzbekistan)
P-36	Preparation and Biodistribution of 99mTc and 188Re Labeled Zoledronic Acid Dr Olga Klementyeva, et al (Russia)
P-37	Radiopharmaceutical Based on Monopotassium Salt of Hydroxyethylendiphosphonic Acid Labeled with 188Re for Therapy of Bone Metastases Dr Vasilij Petriev, et al (Russia)
P-38	Potential Role of Semi-Quantitative Analyses of Bone Metastases in Evaluation of Radionuclide Therapy Response Dr Nigora Rasulova, et al (Uzbekistan)

DAY 2: MONDAY, 26 NOVEMBER 2012

1630 – 1830	SCIENTIFIC SESSION 7: MOLECULAR IMAGING & RADIONUCLIDE THERAPY	Auditorium, Ground Floor
	Session Chairpersons: 1. Dr Michael Tomblin, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA 2. Dr William Macdonald, Nuclear Medicine, Royal Perth Hospital, Perth, Australia	
1630 – 1650 S-14	Potentially required number of PET apparatus in Asia and Latin America including Mexico Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan	
1650 – 1710 S-15	Treatment Response Evaluation using current imaging modalities Prof Rakesh Kumar, Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India	
1710 – 1730 S-16	Avibodies – A Novel Approach for Targeting Prostate and Ovarian Cancer Prof Andrew Scott, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia	
1730 – 1750 S-17	Percutaneous Radionuclide Therapy (PERTH) Prof Ralph McCready, Nuclear Medicine, Royal Sussex County Hospital, Brighton, United Kingdom	
1750 – 1810 S-18	Current Status of PET Radiopharmaceuticals in PET/CT Guided Radiotherapy Treatment Planning Dr Antonija Balenovic, PET/CT Center, Poliklinika Medikol, Zagreb, Croatia	
1810 – 1830 S-13	Development of New Radiopharmaceuticals for Diagnosis and Treatment of Arthritis Prof Vijay Kumar, Nuclear Medicine & PET, Westmead Hospital, Sydney, Australia	
1930 – 2300	FORMAL INAUGURAL CEREMONY	Restaurant Taivas
	<ul style="list-style-type: none"> ▪ WARMTH Awards ▪ Dinner 	
2300	END OF DAY 2	

DAY 3: TUESDAY, 27 NOVEMBER 2012

0810 – 0930	SCIENTIFIC SESSION 8: WARMTH: HISTORY, FUTURE PERSPECTIVES & INTERNATIONAL COLLABORATIONS	Auditorium, Ground Floor
Session Chairpersons: 1. Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia 2. Dr Suresh Srivastava, Collider-Accelerator Department, Brookhaven National Laboratory, New York, USA		
0810 – 0830 S-20	History of WARMTH Prof Ajit Kumar Padhy, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
0830 – 0850 S-21	IAEA Perspectives on Radionuclide Therapy Prof Adriano Duatti, Nuclear Applications, IAEA, Vienna, Austria	
0850 – 0910 S-22	WFNMB Perspectives on Radionuclide Therapy Prof Andrew Scott, President Elect, WFNMB (2014-2018), Australia	
0910 – 0930 S-23	Future Prospects of Radionuclide Therapy in Korea Prof Dong Soo Lee, Nuclear Medicine, Seoul National University Hospital, Seoul, Korea	
0930 – 1105	SCIENTIFIC SESSION 9: NEURO-ENDOCRINE TUMORS I	Auditorium, Ground Floor
Session Chairpersons: 1. A/Prof Grzegorz Kaminski, Endocrinology & Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland 2. Dr Vikram Lele, Director, Nuclear Medicine, Jaslok Hospital & Research Centre, Mumbai, India		
0930 – 0955 S-24	Personalized Radionuclide Therapy of Cancer – Will It Remain a Dream or Become Reality? Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany	
0955 – 1020 S-25	Innsbruck Medical University: Long-term Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria	
1020 – 1045 S-26	NETs: Labeled Somatostatin Analogues in Therapy Dr Chiara Grana, Nuclear Medicine, European Institute of Oncology, Milano, Italy	
1045 – 1105 S-27	Clinical Trial Evaluation of Radiopeptide Therapy of Neuroendocrine Tumours Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia	
1105 – 1130	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION	
1105 – 1130	POSTER PRESENTATIONS	
Session Coordinators: 1. Dr Marika Vereb, Nuklearmedizin, Klinikum Kassel, Kassel, Germany 2. Dr Masha Maharaj, Nuclear Medicine, Polokwane Provincial Hospital, University of Limpopo, Pietersburg, South Africa		
P-39	Selective Internal Radiation Therapy using Yttrium-90 Microspheres: A Practical Demonstration of Personalised Artery Specific Dosimetric Modeling Ms Toh Ying, et al (Singapore)	
P-40	Production and Quality Control of [166 Ho]-DOTA-Bevacizumab for Therapeutic Applications Dr Alireza Khorrami, et al (Iran)	
P-41	Assessment of Human Effective Absorbed Dose of 67Ga-ECC Based on Biodistribution Rat Data Dr Hassan Yousefnia, et al (Iran)	
P-42	Radiation Safety Consideration in 90Y- Microsphere Therapy Dr Ashish Jha, et al (India)	
P-43	SPECT/CT & PET/CT in Imaging Neuroendocrine Tumours: Pearls and Patterns Dr Sadia Salam, et al (Bangladesh)	
P-44	Fast Preparation of 131I-MIBG for Therapy Purposes in Nuclear Medicine Dr Ali Sattari, et al (Iran)	
P-45	Ga-68 DOTATATE PET/CT in Tumour-Induced Osteomalacia Dr Ammad Al Tamimi, et al (Singapore)	

DAY 3: TUESDAY, 27 NOVEMBER 2012

P-46	Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Progressive Neuroendocrine Neoplasms Dr Harshad Kulkarni, et al (India)	
P-47	Role of Ga-68 Somatostatin Receptor PET/CT in the Determination of Molecular Response to Radiofrequency Ablation of Hepatic Metastases from Neuroendocrine Neoplasms Dr Harshad Kulkarni, et al (India)	
P-48	Believe it or Not! Renal Function can Actually Improve after Peptide Receptor Radionuclide Therapy Dr Harshad Kulkarni, et al (India)	
1130 – 1310	SCIENTIFIC SESSION 10: NEURO-ENDOCRINE TUMORS II / LYMPHOMA	Auditorium, Ground Floor
Session Chairpersons: 1. Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany 2. Prof Bozena Birkenfeld, Nuclear Medicine, Uni Lubelskiej, Szczecin, Poland		
1130 – 1150 S-28	An Update on PRRT in India Dr Vikram Lele, Nuclear Medicine, Jaslok Hospital & Research Centre, Mumbai, India	
1150 – 1210 S-29	Somatostatin Analogs as Possible Theragnostic Molecules for Advanced Prostate Cancer Prof Omar Alonso, Nuclear Medicine, Clinical Hospital, University of Uruguay, Montevideo, Uruguay	
1210 – 1230 S-30	Phase II Study of First-Line Iodine-131-Rituximab Radioimmunotherapy of Follicular Non-Hodgkin Lymphoma: The INITIAL Study Dr William Macdonald, Nuclear Medicine, Royal Perth Hospital, Perth, Australia	
1230 – 1250 S-31	Low-Dose, Involved Field Radiotherapy Just Prior to Radioimmunotherapy for Relapsed/Refractory B-Cell Lymphoma Dr Michael Tomblin, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA	
1250 – 1310 S-32	Radioimmunotherapy (RIT) of Follicular Non Hodgkin's Lymphoma (FNHL). The State of the Art Prof Izak Garty, Nuclear Medicine, Central Emek Hospital, Afula, Israel	
1310 – 1400	LUNCH / TRADE EXHIBITION	Restaurant Okta, Ground Floor Hotel Levi Panorama
1400 – 1540	SCIENTIFIC SESSION 11: DOSIMETRY / RADIOPHARMACY	Auditorium, Ground Floor
Session Chairpersons: 1. Prof Frank Roesch, Institute of Nuclear Chemistry, University of Mainz, Mainz, Germany 2. Prof Vijay Kumar, Nuclear Medicine & PET, Westmead Hospital, Sydney, Australia		
1400 – 1420 S-3	Paving the Way to Personalized Medicine for Treatment of Cancer and Inflammatory Disorder Dr Suresh Srivastava, Collider-Accelerator Department, Brookhaven National Laboratory, New York, USA	
1420 – 1430 S-61	Tin-117m-DOTA-Annexin for Imaging and Treating Vulnerable Plaque Dr Gilbert Gonzales, Collider-Accelerator Department, Brookhaven National Laboratory, New York, USA	
1430 – 1440	What it takes to Build a Radiopharmaceutical Product in the Age of Dwindling Financial support Dr Immanuel Thangaraj, Essex Woodlands Health Ventures (EWHV), USA	
1440 – 1500 S-34	Personalized Image-Based Dosimetry for Radionuclide Therapies Prof Anna Celler, Radiology, UBC, VGH Research Pavilion, Vancouver, Canada	
1500 – 1520 S-35	A New Approach of Individual Dosimetry Dr Matthias Blaickner, Health & Environment Department, Biomedical Systems, AIT Austrian Institute of Technology, Vienna, Austria	
1520 – 1540 S-36	New Options to Label Biomolecules with Trivalent Radiometals Adding Non-Aqueous Solvents Prof Frank Roesch, Institute of Nuclear Chemistry, University of Mainz, Mainz, Germany	

DAY 3: TUESDAY, 27 NOVEMBER 2012

1540 – 1600	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION
1540 – 1600	POSTER PRESENTATIONS
P-49	Evaluation and Calculation of Human Absorbed Dose of Tl(III)-201F -DTPA-HlgG based on Biodistribution Data in Rats Dr Alireza Khorrami, et al (Iran)
P-50	Assessment of Human Effective Absorbed Dose of 111In-DTPA-Buserelin Based on Biodistribution Rat Data Dr A Lahooti, et al (Iran)
P-51	Biodistribution of an Ultra Small Super Paramagnetic Iron Oxide Nano Particles in Balb/c Mice Dr Saeed Shanehsazzadeh, et al (Iran)
P-52	Development of a Radiolabeled Glucagon for SPECT Imaging Ms Mahdokht Jouiaei, et al (Iran)
P-53	Biological and Dosimetry Studies of Four Radiolabeled of Rituximab for Human Based on Distribution Data in Rats Dr Edalat Radfar, et al (Iran)
P-54	Investigating the Effectiveness of Low Dose and High Dose Radioiodine Ablation for Post Surgical Thyroid Remnants in Patients with Differentiated Thyroid Carcinoma at Kuala Lumpur Hospital Dr Nor Salita Ali, et al (Malaysia)
P-55	Evaluation and Dosimetry Studies of Human Absorbed Dose of Various Age Groups of 90Y-DOTA-Cetuximab Based on Distribution Data in Rats Dr Ariandokht Vakili, et al (Iran)
P-56	Development of Ho-166 Chitosan for Hepatocellular Carcinoma Dr Hassan Yousefnia, et al (Iran)
P-57	Development and Characterization of Clinical-Grade 64Cu-DOTA-Trastuzumab for HER2/Neu Oncology Imaging Using Dual Head SPECT Dr Behrooz Alirezapour, et al (Iran)
P-58	In-Vitro and In-Vivo Evaluations of a Novel Potential Folate Receptor Imaging Agent Dr Esmail Mollarazi, et al (Iran)
P-59	Synthesis, Quality control, Biological Evaluation by a Kinetic Model of [90Y]-DOTA-Cetuximab for Radioimmunotherapy Purpose Dr Ariandokht Vakili, et al (Iran)
P-60	Development of a New In-111 Quinolone Complex as a Possible Imaging Agent Dr Yousef Fazaeli, et al (Iran)
P-61	Development of In-111 and Ga-67 Maltolate Complexes as Imaging Agents Dr Yousef Fazaeli, et al (Iran)
P-62	Synthesis, Radiolabeling and Biological Evaluation of a New 111Indium-Porphyrin Complex as an Imaging Agent Dr Yousef Fazaeli, et al (Iran)
P-63	Synthesis, Characterization and Biological Evaluation of a new 131Iodo porphyrin complex as an imaging agent Dr Yousef Fazaeli, et al (Iran)
P-64	Synthesis, labeling optimization and Biological Evaluation of 111Indium 5,10,15,20-Tetrakis (3,5-di Hydroxyphenyl) Porphyrin Complex as an Imaging Agent Dr Yousef Fazaeli, et al (Iran)
P-65	Our Experience in the Safe and efficient delivery of Radionuclide Therapy for Neuroendocrine Tumors with Lu-177 DOAT-TATE Mr S Somanesan, et al (Singapore)
P-66	Preparation and Quality Control of Lutetium-177 Bleomycin as a Possible Therapeutic Agent Dr Hassan Yousefnia, et al (Iran)
P-67	Development of [177Lu]-Tetra Phenyl Porphyrin Complexes as Possible Imaging Agents Dr Hassan Yousefnia, et al (Iran)

DAY 3: TUESDAY, 27 NOVEMBER 2012

1600 – 1740	SCIENTIFIC SESSION 12: DEVELOPMENTS IN THERAPEUTIC RADIOPHARMACEUTICALS	Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Alan Perkins, Radiological & Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom 2. Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria	
1600 – 1620 S-38	Nanostructures and Their Multiplex Labeling with Targeting Ligands and Radioisotopes Prof Jae Min Jeong, Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea	
1620 – 1640 S-39	Prospects of Lu-177/Y-90 Production and Future Radionuclide Therapy in Korea Dr Sun-Ju Choi, Director, Radioisotope Research Division, Korea Atomic Energy Research Institute, Daejeon, Korea	
1640 – 1700 S-40	Experience of Platform Construction and Clinical Trial of New Radionuclide Therapy in Korea Dr Gi Jeong Cheon, Nuclear Medicine, Korea University, Seoul, Korea	
1700 – 1720 S-41	Introducing the Animal Models for Evaluation of New or/and Already Existing Radiopharmaceuticals Prof Emilija Janevik-Ivanovska, University "Goce delcev", Faculty of Medical Sciences, Stip, Republic of Macedonia	
1720 – 1740 S-37	Review of Available and Future Radionuclides Useful for Radiotherapeutics: Industrial and Regulatory Limitations Dr Richard Zimmermann, Chrysalium Consulting, France	
1740 – 1815	SCIENTIFIC SESSION 13: RADIONUCLIDE THERAPY QUIZ	Auditorium, Ground Floor
	Session Chair & Moderator: 1. Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom	
1815 – 1930	WARMTH MEMBERS' ASSEMBLY ALL MEMBERS OF WARMTH TO ATTEND THE MEETING	Auditorium, Ground Floor
1930	END OF DAY 3	
1930	FREE EVENING (Participants to plan their own activities)	

DAY 4: WEDNESDAY, 28 NOVEMBER 2012		
0800 – 0910	SCIENTIFIC SESSION 14: ALPHA THERAPY	Auditorium, Ground Floor
Session Chairpersons: 1. Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany 2. Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan		
0800 – 0825 S-42	Radium-223 (Alpharadin) in The Treatment Of Skeletal Metastases in Prostate Cancer Patients Prof Øyvind S Bruland, Onclogy, University of Oslo, Norwegian Radium Hospital, Oslo, Norway	
0825 – 0850 S-43	GlioblastomaTherapy with Substance P labelled with Bismuth-213 – Initial Experience Prof Leszek Królicki, Dr Jolanta Kunikowska, Dr Henryk Koziara, Dr Alfred Morgenstern, F Bruchertseifer, Maciej Jakuciński, Dr Dariusz Pawlak, Dr Renata Mikołajczak, Dr Bartosz Królicki and Dr Sławomir Barszcz Nuclear Medicine Department, Medical University of Warsaw, POLAND; European Commission, Joint Research Centre, Institute for Transuranium Elements; Institute of Oncology, Maria Skłodowska-Curie Memorial Cancer Center, Warsaw Branch, Warsaw, Poland; Nuclear Medicine Department Brodnowski Hospital, Warsaw, Poland; National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock-Swierk Poland (To be presented by Dr Jolanta Kunikowska)	
ORAL PRESENTATIONS Auditorium, Ground Floor		
0850 – 0900 O-9	Cis-Diamminedichloroplatinum (II) Enhancement of Antitumor Effect of In-111-Labeled N-Myc Antisense Oligonucleotides in Nude Mouse-Grown Human Neuroblastoma Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan	
0900 – 0910 O-10	Ki67 or/and 18FDG PET/CT? Which Do We Need for Qualification Patients to Peptide Receptor Radionuclide Therapy (PRRT) ? Dr Jolanta Kunikowska, Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland	
0910 – 1100	SCIENTIFIC SESSION 15: BREAST CANCER & MISCELLANEOUS	Auditorium, Ground Floor
Session Chairpersons: 1. Dr Gregory Wiseman, Mayo Clinic, Minnesota, USA 2. Dr Nei Wen Long, Radiation Oncology, National Cancer Centre Singapore, Singapore		
0910 – 0935 S-44	Contribution of Nuclear Medicine in Early Breast Cancer: From Sentinel Node to IART® (Intra-Operative Avidination For Radionuclide Therapy) Dr Chiara Grana, Nuclear Medicine, European Institute of Oncology, Milano, Italy	
0935 – 0955 S-45	Positron Emission Mammography (PEM): A Perspective Dr Patricia Bernal, Nuclear Medicine, Fundacion Santa Fe de Bogota, Bogota, Colombia	
0955 – 1020 S-62	Oncolytic Viral Therapy Prof Akseli Hemminki, University of Helsinki / Docrates Cancer Center, Finland	
1020 – 1040 S-46	Statistics – Interesting and Useful Prof Janez Stare, Biostatistics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia	
1040 – 1100 S-47	Role of Nuclear Medicine in Oncological Surgery Prof Bożena Birkenfeld, Nuclear Medicine, Uni Lubelskiej, Szczecin, Poland	
1100 – 1130	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION/ POSTER VIEWING	

DAY 4: WEDNESDAY, 28 NOVEMBER 2012	
	POSTER PRESENTATIONS
Session Coordinators: 1. Dr Butch Magsombol, Nuclear Medicine & PET, Singapore General Hospital, Singapore. 2. Dr Lucia Kaliska, Nuclear Medicine, Institute of Nuclear Medicine & Molecular Medicine, Banská Bystrica, Slovakia	
P-68	Role of PET/CT in Initial Staging of Lung Cancer Dr Xuan Canh Nguyen, et al (Vietnam)
P-69	Pleuroperitoneal Communication Detected by Technetium 99m-tagged Macroaggregated Albumin (MAA) Radionuclide Peritoneal Scintigraphy in a Chronic Kidney Disease Patient on Peritoneal Dialysis: A Case Report Ms Carla Mari Macaísa, et al (Philippines)
P-70	Significant Impact of a Single End of Treatment F-18 FDG PET/CT Study as a Prognostic Indicator and Predictor of Final outcome in Non-Metastatic Squamous Cell Carcinoma of Head and Neck Region Dr Partha Choudhury, et al (India)
P-71	SPECT-CT for the Diagnosis of Primary Hyperparathyroidism Dr Marina Garcheva, et al (Bulgaria)
P-72	Variations of Gates' GFR Among Different Work Stations Mr Rey Martin Jr Goco (Philippines)
P-73	Measurement of Non-Uniformity in Gamma Cameras: Effect of Crystal Hydration Dr Milena Dimcheva, et al (Bulgaria)
P-74	Correlation of Wall Motion Score and Left Ventricular Ejection Fraction by Gated SPECT Myocardial Perfusion Imaging Prof Raihan Hussain, et al (Bangladesh)
P-75	PET/CT & SPECT/CT in Imaging Prostate Cancer: Tracers, Advantages & Limitations Dr Sadia Salam, et al (Bangladesh)
P-76	Clinical Interest of Hybrid Imaging in Lung Cancer Prof Ben Rais Aouad Nozha, et al (Morocco)
P-77	The Clinical Impact of 18-F Fluorocholine PET/CT in the Management of Prostate Cancer Dr Anbalagan Kannivelu, et al (Singapore)
P-78	The Role of Sentinel Lymph Node Biopsy in the Prediction of Metastatic Spread of Malignant Melanoma Dr Anca Zamfirescu, et al (Romania)
P-79	Role of Contrast Enhanced 18F- FDG PET- CT in Restaging of Pancreatic Carcinoma Dr Arun Gandhi, et al (India)
P-80	Controversy over Dense Breast Imaging: Are We Using All the Armaments in Our Arsenal; A Review of Molecular Breast Imaging's Potential Role in the Battle Against Breast Cancer Dr S Krishna Kumar, et al (Singapore)
P-81	Site Specific Radioiodination of HER2-Targeting Affibody Molecules Using Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity Strand J, Nordeman P, Honarvar H, Altai M, Larhed M, Orlova A, Tolmachev V Uppsala University, Uppsala, Sweden
P-82	Is PET and PET/CT useful in Pediatrics? De Leon D, Dr Emerita Barrenechea (Philippines)
P-83	Developing a Nuclear Medicine Outreach Program. The Polokwane Experience Dr Masha Maharaj (South Africa)
P-84	Tc-99m MIBI Scan in Multiple Myeloma Dr Raluca Mittelul, et al (Romania)

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 4: WEDNESDAY, 28 NOVEMBER 2012		
1130 – 1310	SCIENTIFIC SESSION 15: LIVER AND GI CANCER	Auditorium, Ground Floor
Session Chairpersons: 1. Dr Patricia Bernal, Nuclear Medicine, Fundacion Santa Fe de Bogota, Bogota, Colombia 2. Prof Jae Min Jeong, Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea		
1130 – 1150 S-48	Clinical use of Rhenium-188 from the Tungsten-188/Rhenium-188 Generator Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany	
1150 – 1210 S-49	SIR-Spheres in HCC Dr Jaroslaw Cwikla, Nuclear Medicine, Faculty of Medical Science, University of Varmia and Masuria Olsztyn Poland	
1210 – 1230 S-50	Re-188 Lipiodol Therapy for HCC – A New Approach and Perspective from the Rhenium Users' Group Prof Ajit Kumar Padhy, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1230 – 1250 S-51	I-131-Lipiodol Therapy in Local Disease Control and Survival in Patients with Advanced Hepatocellular Carcinoma and Metastatic Liver Disease from other Primary Tumors: Our Initial Experience Dr Kumarswamy Kallur, Nuclear Medicine, Healthcare Global Enterprises Pvt Ltd, Bangalore, India	
1250 – 1310 S-52	Therapy of Colorectal Cancer Tumours with an Agonist DR5 Antibody Prof Andrew Scott, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia	
1310 – 1410	LUNCH / TRADE EXHIBITION	Restaurant Okta, Ground Floor Hotel Levi Panorama
1410 – 1550	SCIENTIFIC SESSION 16: MISCELLANEOUS/NEW THERAPIES/ FUTURE TRENDS	Auditorium, Ground Floor
Session Chairpersons: 1. Dr Chiara Grana, Nuclear Medicine, European Institute of Oncology, Milano, Italy 2. Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines		
1410 – 1430 S-53	Outside the Box: Challenging Cases for Radioimmunotherapy Dr Michael Tomblin, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA	
1430 – 1450 S-54	Ancient Features of Personalizing Cancer Treatment; Learning from Radionuclide Therapy in the Era of Targeted Therapies Dr So Won Oh, Nuclear Medicine, Seoul National University Boramae Hospital, Seoul, Korea	
1450 – 1510 S-55	Quantitative Imaging of Radiotracer Biodistributions Prof Anna Celler, Radiology, UBC, VGH Research Pavilion, Vancouver, Canada	
1510 – 1530 S-56	Quality of Life (QOL) Assessment in Neuroendocrine Tumor (NET) Patients Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria	
1530 – 1550 S-57	Quality of Life in Oncological patients and Radionuclide Therapy Mr William Claxton, Carcinoid & Neuroendocrine Tumor Society, Singapore	
1550 – 1615	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION	
1615 – 1645	SCIENTIFIC SESSION 17: RADIONUCLIDE THERAPY QUIZ	Auditorium, Ground Floor
Session Chair & Moderator: 1. Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom		
1645 – 1725	SCIENTIFIC SESSION 18: FINAL SESSION	Auditorium, Ground Floor
Session Chairpersons: 1. Prof Andrew Scott, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia 2. Prof Abdelhamid Elgazzar, Medical Faculty, University of Kuwait, Safat, Kuwait		
1645 – 1705 S-58	Radionuclide Therapy: From Radium to Radium Prof Alan Perkins, Radiological and Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom	
1705 – 1725 S-59	Outpatient Therapeutic Oncology Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia	

DAY 4: WEDNESDAY, 28 NOVEMBER 2012

Venue: Levi Summit Conference Centre, Levi, Finland

1725 – 1815	WARMTH MEMBERS' ASSEMBLY ALL MEMBERS OF WARMTH TO ATTEND THE MEETING	Auditorium, Ground Floor
1815 – 1930	CLOSING	Auditorium, Ground Floor
Awards: Best Oral presentations & Posters		
Impressions from Participants		
Welcome to ICRT 2013 (Cairo, Egypt) Prof Abdelhamid Elgazzar, Local Organising Chairman, ICRT 2013		
Declaration of Results of WARMTH Elections for The Next Governing Body (2013 – 2014)		
Impressions Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany		
Impressions Prof Alan Perkins, Radiological and Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom		
Impressions Prof Kalevi Kairemo, Local Organising Chairman, ICRT 2012		
Closing Remarks Prof Ajit Kumar Padhy		
1930	END OF SCIENTIFIC PROGRAM	
2000	DINNER: Theme "Blue Dress" Participants are requested to wear something blue (Any shade of blue)	Restaurant Okta, Ground Floor Hotel Levi Panorama
2300	END OF DAY 3	

DAY 5: THURSDAY, 29 NOVEMBER 2012

SIGHT-SEEING TOUR & OENOPHILOUS DINNER		
0830	Departure from Hotel	
0830 – 1200	Whole Day Excursion To Rovaniemi: Part I <ul style="list-style-type: none"> Arctic Circle Santa Claus Village Arctic Science Museum 	
1200 – 1400	LUNCH	
1400 – 1800	Whole Day Excursion To Rovaniemi: Part II <ul style="list-style-type: none"> Arctic Circle Santa Claus Village Arctic Science Museum 	
1800 – 2200	Oenophilous Dinner & Closing	

DAY 6: FRIDAY, 30 NOVEMBER 2012

Departure to respective countries